Developments in Tissue Engineered and Regenerative Medicine Products

Index

A

adipose, 38, 45, 57–9, 61, 67–8, 74, 78–81, 89, 97, 109–10, 117

ADME Tox, 149–50

ADMET, 149–53

alternate cell sourcing, 45, 79

animal models, 17, 33, 40, 103, 149, 154

B

bill of materials, 167, 179

biocompatibility, 32, 35, 49, 107, 149, 152, 181

Biomaterials, 1–3, 5, 21–3, 26, 29–42, 45, 48–50, 60, 62, 67, 70, 88, 101–2, 104–5, 107–11, 114, 117–20, 149, 152, 178

biopolymer, 49, 51, 57, 60, 80–1, 101

bladder augmentation, 37, 45–6, 48, 179

bladder replacement, 2, 45–6, 49

C

chronic kidney disease, 17, 21, 30, 101, 106

chronic obstructive pulmonary disease, 87, 89

combination product, 21, 73, 149, 151, 179

compliance training, 125

critical areas, 143, 167, 172

cystectomy, 3, 37, 45, 47, 51, 54, 61, 78–83

D

decell/recell, 21